# Weiss Ratings

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/weiss-ratings
Canonical HTML page: https://gethealthbrief.com/entity/weiss-ratings

## Recent coverage (2 stories)

### ResMed Faces $270.64 Consensus Target Amid Analyst Divide on Sleep Device Demand
2026-07-10 14:15:23 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Analyst downgrades reflect growing fears that GLP-1 weight loss drugs could erode the sleep apnea device market, even as ResMed’s financials stay solid. The contrast between a $225 low target and $321 high target underscores sector uncertainty.
Full story: https://gethealthbrief.com/story/resmed-analyst-target-sleep-apnea-demand

### Shuttle Pharma Insider Spends $110K on 32.5K Shares at 94% Discount from High
2026-07-05 23:48:59 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

A major Shuttle Pharmaceuticals shareholder just poured $110,694 into the beaten-down stock, buying 32,591 shares at near all-time lows. For healthcare investors, this insider vote of confidence in a radiation oncology developer could signal upcoming clinical catalysts or a potential turnaround.
Full story: https://gethealthbrief.com/story/shuttle-pharma-insider-buying-signal-healthcare

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.